Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
World Journal of Gastroenterology, 23 (36), 66506664
When we use QALYs, the VBP becomes $10,817, implying that the larger weight reduction and more inclusive accounting of obesity-related health impacts together add about 12% to the estimate of value, compared to ICER
In this particular case, were providing additional access to beneficiaries who wouldnt otherwise be covered by Medicare for obesity indications, and so theres access to additional patients who could really benefit from these medications, and thats mutually beneficial for both the taxpayer, for those beneficiaries, as well as for the companies
Ba, 2018
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
US$ 25.14
US$ 24.62
US$ 29.68
US$ 25.79
